Skip to content
value.today

Ophthotech Corp.

Total raised
$35 M
3 rounds on record
Latest round
$17 M
May 2013
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Ophthotech Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$11 MIssued in a merger or acquisition$10 to $50 million

Ophthotech Corp.: Private sale, Oct 2018

Investors in this round

2 investors had bought by the notice of Nov 2, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Ophthotech Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $12 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Guyer · Executive Officer, Director
  • David Pritchett Carroll · Executive Officer
  • Glenn Sblendorio · Executive Officer, Director
  • Keith Pritchett Westby · Executive Officer
  • Axel Bolte · Director
  • David Pritchett Redlick · Director
  • Jane Pritchett Henderson · Director
  • Michael Ross · Director
  • Thomas Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Todd Anderman, General Counsel. Source: SEC Form D, newest notice filed Nov 2, 2018. Read the notice at the SEC.

equitySEC
May 2013$17 MNo. 3$10 to $50 million

Ophthotech Corp.: Raise no. 3, May 2013

Investors in this round

7 investors had bought by the notice of Jun 3, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Ophthotech Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $50 M offered; $33 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce C. Peacock · Executive Officer
  • David C. Guyer · Executive Officer, Director
  • Evelyn C. Harrison · Executive Officer
  • Samir C. Patel · Executive Officer, Director
  • Axel C. Bolte · Director
  • Michael C. Ross · Director
  • Nicholas C. Galakatos · Director
  • Thomas C. Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bruce Peacock, Chief Business Officer. Source: SEC Form D, newest notice filed Jun 3, 2013. Read the notice at the SEC.

equitySEC
Dec 2009$15 MNo. 2$10 to $50 million

Ophthotech Corp.: Raise no. 2, Dec 2009

Investors in this round

7 investors had bought by the notice of Dec 18, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Ophthotech Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Evelyn C. Harrison · Executive Officer
  • Samir C. Patel · Executive Officer, Director
  • Thomas C. Biancardi · Executive Officer
  • Alex C. Bolte · Director
  • David C. Guyer · Director
  • Henry C. Simon · Director
  • Nicholas C. Galakatos · Director
  • Thomas C. Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samir C. Patel, President. Source: SEC Form D, newest notice filed Dec 18, 2009. Read the notice at the SEC.

equitySEC
Oct 2009$3 MNo. 1$2 to $10 million

Ophthotech Corp.: Raise no. 1, Oct 2009

Investors in this round

5 investors had bought by the notice of Oct 19, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Ophthotech Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Evelyn C. Harrison · Executive Officer
  • Samir C. Patel · Executive Officer, Director
  • Thomas C. Biancardi · Executive Officer
  • Alex C. Bolte · Director
  • David C. Guyer · Director
  • Henry C. Simon · Director
  • Thomas C. Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samir C. Patel, President. Source: SEC Form D, newest notice filed Oct 19, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ophthotech Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2018

That is all the official record says: Ophthotech Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Ophthotech Corp.
InvestorKindAmountRoundRoleSource
Clarus Lifesciences II, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Clarus Ventures II GP, L.P.Venture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Clarus Ventures II, LLCVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
HBM Healthcare Investments (Cayman) Ltd.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
SV Life Sciences Fund IV (GP), L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
SV Life Sciences Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
SV Life Sciences Fund IV Strategic Partners, L. P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Svlsf IV, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ophthotech Corp.
NameRoleNamed in
David GuyerExecutive officerNov 2018
David Pritchett CarrollExecutive officerNov 2018
Glenn SblendorioExecutive officerNov 2018
Keith Pritchett WestbyExecutive officerNov 2018
Bruce C. PeacockExecutive officerJun 2013
David C. GuyerExecutive officerJun 2013
Evelyn C. HarrisonExecutive officerJun 2013
Samir C. PatelExecutive officerJun 2013
Thomas C. BiancardiExecutive officerDec 2009
Axel BolteDirectorNov 2018
David GuyerDirectorNov 2018
David Pritchett RedlickDirectorNov 2018
Glenn SblendorioDirectorNov 2018
Jane Pritchett HendersonDirectorNov 2018
Michael RossDirectorNov 2018
Thomas DyrbergDirectorNov 2018
Axel C. BolteDirectorJun 2013
David C. GuyerDirectorJun 2013
Michael C. RossDirectorJun 2013
Nicholas C. GalakatosDirectorJun 2013
Samir C. PatelDirectorJun 2013
Thomas C. DyrbergDirectorJun 2013
Alex C. BolteDirectorDec 2009
Henry C. SimonDirectorDec 2009

About

Company in New York, United States.